KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.96

Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis.

Lucjan Wyrwicz, Vasiliki Kalampoki, Adriana Valderrama, Kate Young

Immunotherapy 18(3) 161-167

PMID41964430
PMCIDPMC13155006
DOI10.1080/1750743X.2026.2647579
发表日期2026-04-11
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

AIMS: In KEYNOTE-859, pembrolizumab plus chemotherapy significantly improved overall survival (OS) versus placebo plus chemotherapy for participants with untreated locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma, with manageable safety. This post hoc analysis assessed Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST). PARTICIPANTS AND METHODS: Survival time was grouped into three health states: TOX (time with any grade ≥3 adverse event [AE] before disease progression), TWiST (time before PD or death without grade ≥3 AEs), and REL (time from PD to death). Q-TWiST was the sum of restricted mean survival time (RMST) in each state, weighted by utilities estimated using the EQ-5D-5L questionnaire. Relative gains in Q-TWiST ≥15% were considered "clearly clinically important." RESULTS: RMST was longer in TOX (2.30 months [95% CI, 1.28 to 3.44]) and TWiST (1.90 months [95% CI, -0.02 to 3.79]) and shorter in REL (-0.28 months [95% CI, -2.43 to 2.01]) with pembrolizumab plus chemotherapy versus chemotherapy at month 56, for a relative Q-TWiST gain of 20.90% (US algorithm) or 18.38% (standardized algorithm). CONCLUSIONS: A clearly clinically important Q-TWiST gain was observed with pembrolizumab plus chemotherapy versus chemotherapy in all participants. CLINICAL TRIALS REGISTRATION: www.ClinicalTrials.gov identifier is NCT03675737.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。